Navigation Links
Rivaroxaban phase III pivotal data presented at EFORT annual meeting
Date:5/30/2008

Nice, France (May 30, 2008) Results from a pivotal Phase III clinical trial presented today demonstrate that rivaroxaban, an oral, once-daily, investigational anticoagulant medication, was superior in preventing venous blood clots in patients who underwent total knee replacement (TKR) surgery. The head-to-head study compared rivaroxaban with the U.S.-approved dosing regimen for enoxaparin, the current standard of care.

Data from the RECORD4 clinical trial were presented at the annual meeting of the European Federation of National Associations of Orthopaedics & Traumatology (EFORT). Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare AG.

The RECORD4 data show that rivaroxaban (10mg once-daily) provided TKR surgery patients a statistically significant 31% relative risk reduction (RRR) in total venous thromboembolism (VTE) events defined in the study as the composite of all deep vein thrombosis, non-fatal pulmonary embolism and all-cause mortality compared to enoxaparin (30mg twice-daily) (6.9% and 10.1%, respectively, p =0.012). Rates of major bleeding, the main safety endpoint, were low in both treatment groups, yet numerically greater in rivaroxaban-treated patients. This difference was not statistically significant from the rate of major bleeding in enoxaparin-treated patients (0.7% and 0.3% respectively; p=0.110). RECORD4 is the third of three, direct, head-to-head comparisons within the RECORD program to demonstrate the superior efficacy of rivaroxaban over enoxaparin with a similar adverse event profile.

"The superior efficacy and similar adverse event profile of rivaroxaban demonstrated in RECORD4 are in line with the outstanding results of the earlier RECORD studies," said Dr. A.G.G. Turpie, Professor of Medicine, McMaster University, Canada and Principal Investigator for the RECORD program. "The success of this trial strengthens my belief that d
'/>"/>

Contact: Stephen Cooper
stephen.cooper@edelman.com
Edelman Public Relations
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. TAK-390MR Phase 3 data presented at Digestive Disease Week
2. Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome
3. New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women
4. AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
5. Phase III pivotal results presented of VYVANSE to treat ADHD in adults
6. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
7. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
8. Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting
9. Wal-Mart Launches Phase Three of $4 Prescription Program
10. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
11. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2015)... Francisco, CA (PRWEB) May 03, 2015 ... (CFHI), announced it will be awarding the 2015 ... Jennifer Knight and Selemawit Ghebrendrias, are the deserving recipients ... champion for global service, Harris Llewellyn Wofford. The two ... service and passion for global health. , CFHI ...
(Date:5/3/2015)... Missouri (PRWEB) May 03, 2015 ... business that will directly impact your career? The ... designed for dynamic leaders in multinational companies and ... company. In a changing global landscape, differences in ... and relationships. The EMIB program develops the global ...
(Date:5/3/2015)... HealthPostures, a pioneering ergonomics company ... appearance at the , May 5 - 7, 2015 ... exhibit at the conference include its bestselling TaskMate sit ... is the 6100 TaskMate Executive. Features of the 6100 ... keyboard tray, extended platform work surface and supply holders. ...
(Date:5/2/2015)... 2015 “ ActOn ” was featured on ... look at the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... with organizations to make a difference. , In this material ... things that aren’t about money, which is why those things ...
(Date:5/2/2015)... “ Peachtree Audio ” was featured ... which features the latest and coolest technology products available ... reporter for NewsWatch, conducted the review and shared with ... , Music is an important part of people’s lives ... given the royal treatment. Peachtree Audio does just that ...
Breaking Medicine News(10 mins):Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2
... nations on Friday plans to sign an agreement to ... including HIV/AIDS, TB //and malaria - that largely affect ... ,Under the program, donor countries will ... a preferential price when they are available. This would ...
... reported in the latest Nature Nanotechnology, aims to make ... system has an extremely tiny sieve structure built into ... fluids and separate proteins accurately by size. Conventional separation ... to process. The new microchip system could sort proteins ...
... rare genetic disease, genetics researchers have identified a novel ... human development, potentially in cases of mental retardation and ... identified two genes that contribute to Cornelia deLange syndrome ... one in 10,000 children. The disease varies from milder ...
... published in the latest Lancet raises hopes of prenatal ... //The technology involves separating fetal DNA and mother's DNA ... copies of chromosome 21. ,Currently, available tests ... causes Down's syndrome--are limited by several factors. Screening tests, ...
... Lilly is set on releasing a new line of digital ... Huma-Pen Memoir is thought //to help patients manage their insulin ... hides a hypodermic needle, was unveiled today at Battelle. It ... Eli Lilly, the Indianapolis-based pharmaceutical company. ,The ...
... from Wake Forest University School of Medicine and colleagues, today's ... body fat. // ,Up until age 80, older adults ... of the obesity epidemic - they actually begin their older ... of diabetes, heart disease, high blood pressure, arthritis and disability, ...
Cached Medicine News:Health News:New Microchip for Protein Sorting 2Health News:New Microchip for Protein Sorting 3Health News:Gene Found for Rare Disorder May Reveal New Pathway in Mental Retardation 2Health News:Obesity and Older Adults 2
(Date:5/1/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), an ... markets products that assist healthcare providers in monitoring patients ... the first quarter ended March 31, 2015. ... continued progress with year over year growth of 44% ... said Doug Murphy-Chutorian , M.D., chief executive officer ...
(Date:5/1/2015)... May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... E. Morris , chief financial officer  will be participating ... are as follows: Mizuho Third Annual Healthcare ... Omni Berkshire Place, New York ...
(Date:5/1/2015)... YORK , May 1, 2015  Shares of ... 70% of their value yesterday following the results of ... glaucoma therapy, Rhopressa.  Despite the trial failing to meet ... that positive results may come from future studies. ... brief company overview, current pipeline, financial review, analyst summary, ...
Breaking Medicine Technology:Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... DIEGO, Oct. 20 Aethlon Medical, Inc. (OTC Bulletin ... the Aethlon Hemopurifier® is effective in capturing the current ... Hemopurifier® is the first-in-class medical device able to selectively ... During invitro studies, the Hemopurifier® removed ...
... , WALTHAM, Mass., Oct. 20 Logical Therapeutics, Inc. ... treat medical conditions associated with inflammation, has been selected ... the gastrointestinal (GI) safety of its lead product LT-NS001, ... Annual Scientific Meeting on October 27, 2009. , ...
Cached Medicine Technology:Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus 2Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus 3Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting 2
For use with catalog #0454....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasmawith heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all free...
Antigenic Total Protein S, ELISA Method...
Medicine Products: